Guided Therapeutics (GTHP) Net Margin (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Net Margin for 16 consecutive years, with 202.71% as the latest value for Q4 2025.
- Quarterly Net Margin rose 6979729.0% to 202.71% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 430.25% through Dec 2025, up 3658404.0% year-over-year, with the annual reading at 430.25% for FY2025, 3658404.0% up from the prior year.
- Net Margin hit 202.71% in Q4 2025 for Guided Therapeutics, up from 1308.33% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 202.71% in Q4 2025 to a low of 70000.0% in Q4 2024.
- Historically, Net Margin has averaged 16039.17% across 5 years, with a median of 4025.0% in 2023.
- Biggest five-year swings in Net Margin: tumbled -6853438bps in 2024 and later surged 6979729bps in 2025.
- Year by year, Net Margin stood at 848.33% in 2021, then tumbled by -4041bps to 35133.33% in 2022, then skyrocketed by 96bps to 1465.62% in 2023, then tumbled by -4676bps to 70000.0% in 2024, then skyrocketed by 100bps to 202.71% in 2025.
- Business Quant data shows Net Margin for GTHP at 202.71% in Q4 2025, 1308.33% in Q3 2025, and 731.62% in Q2 2025.